📣From lead to pre-candidate nomination in 18 months. Explore the STORM Therapeutics case study

Contact
  • Integrated Drug Discovery

    Integrated Drug Discovery

    Overview

    We deliver truly integrated drug discovery programs. Our co-located teams accelerate compounds from target ID to candidate.

  • Target Identification & Validation

    Target Identification & Validation

    It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.

  • Hit Identification

    Hit Identification

    Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.

  • Hit-to-Lead

    Hit-to-Lead

    High-quality hits with early proof of concept are de-risked and profiled, ready to accelerate your program towards lead optimization.

  • Lead Optimization

    Lead Optimization

    Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.

Featured Resources

  • Modalities

    Modalities

    Overview

    Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.

  • Small Molecules

    Small Molecules

    Expert small molecule discovery from target ID to scale-up, delivering candidates designed for success and market impact.

  • Peptides

    Peptides

    Transforming complex peptide concepts into next-generation therapies through integrated design, advanced analytics, and collaborative end-to-end discovery expertise.

  • Targeted protein degradation

    Targeted protein degradation

    Leveraging induced proximity and CHARMED technology to rapidly design, test, and optimize degraders for previously ‘undruggable’ targets.

  • ADCs

    ADCs

    Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.

  • Biologics

    Biologics

    Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.

Featured Resources

  • Therapeutic Areas

    Therapeutic Areas

    Overview

    Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.

  • Oncology and Immuno-Oncology

    Oncology and Immuno-Oncology

    Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.

  • Inflammation and Immunology

    Inflammation and Immunology

    Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.

  • Neuroscience

    Neuroscience

    Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.

  • Metabolic Diseases

    Metabolic Diseases

    Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.

Featured Resources

  • CellCentric Lead Optimisation Campaign - CCS1477

    CellCentric Lead Optimisation Campaign - CCS1477

    Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.

    Case study
  • About Sygnature

    About Sygnature

    At Sygnature Discovery, we deliver world-leading drug discovery solutions to accelerate your compound from idea to clinic.

  • Meet our Team

    Meet our Team

    Our leadership team brings diverse experience and insight, driving collaboration and innovation across drug discovery.

  • Careers

    Careers

    Explore careers at Sygnature Discovery and join a global team committed to science, collaboration, and integrity.

Search Results

Search across news, resources and pages to quickly find relevant content on our site.

Loading…
Blog
High throughput screening of inverse agonists
Explore our innovative approach to screening GPCR inverse agonists and discover the therapeutic potential of these compounds in drug discovery. Learn how we developed robust HTS assays, screened hundreds of compounds, and advanced our drug discovery pipeline with precision and efficiency.
Journal Papers
Sebetralstat (KVD900): A Potent and Selective Small Molecule Plasma Kallikrein Inhibitor Featuring a Novel P1 Group as a Potential Oral On-Demand Treatment for Hereditary Angioedema
Rebecca L. Davie, Hannah J. Edwards, D. Michael Evans, Simon T. Hodgson, Michael J. Stocks,…
Blog
Sygnature Discovery Partners with Insmed to develop first-in-class compounds for genetically defined diseases
Sygnature Discovery collaborates with Insmed, bringing together their expertise to develop compounds targeting genetically defined diseases. With seamless teamwork and co-located scientific operations, they aim to create innovative therapeutics for unmet medical needs.
Journal Papers
Melatonin and Its Metabolites Can Serve as Agonists on the Aryl Hydrocarbon Receptor and Peroxisome Proliferator-Activated Receptor Gamma
Andrzej T Slominski, Tae-Kang Kim, Radomir M Slominski, Yuwei Song, Shariq Qayyum, Wojciech Placha, Zorica Janjetovic, Konrad KleszczyÅ„ski, Venkatram Atigadda, Yuhua Song, Chander Raman, Cornelis J…
Blog
Formulating PROTACS and other Targeted Protein Degraders
Delve into the realm of targeted protein degradation and the critical role of formulation strategies in drug development. From overcoming dissolution limitations to optimizing stability and solubility, explore the key components that ensure your molecule's clinical success. Sygnature Discovery offers comprehensive formulation support, bringing your degrader one step closer to achieving its full potential.
Blog
Targeting the 5-HT2A receptor with psychedelics & novel molecules
Dive into the world of 5-HT2A receptor modulation, DMPK, and novel psychedelics. Learn how these aspects impact therapeutic responses and discover our exciting research at SfN 2023.
News
Sygnature Discovery invests £3.75M in Compound Management to provide cutting-edge hit finding capabilities to pharma and biotechnology customers
Sygnature Discovery has unveiled its latest investment in a state-of-the-art Azenta compound management storage…
Blog
Targeting Neuroinflammation: Using the Right Tools/Models to Decipher the Brain’s Immune Response and Evaluate Novel Drug Candidates
Dive into the world of neuroinflammation research, featuring insights on in vitro models, in vivo testing, and stay updated with upcoming presentations at the Society for Neuroscience (SfN) event. Explore the latest in CNS drug discovery and innovation.
News
Sygnature Discovery Appoints Industry Leaders To Board Of Directors
Sygnature Discovery is thrilled to announce the appointment of two esteemed industry professionals,…
Blog
Can small molecules compete with Ozempic and Wegovy and take a seat at the GLP-1 dinner table?
Over the last decade, GLP-1 therapies have transformed diabetes and obesity treatment. Discover the potential of small molecules in this field and their role in revolutionizing treatment options and improving patient outcomes.
Blog
Bold minds, Serendipitous Discoveries: The True Basis of Drug Innovation
Delve into drug discovery's dynamic blend of logic and learning, where Pasteur's foresight meets the bold pursuit of serendipitous opportunities. From crafting hypotheses to exploring unexpected outcomes, a prepared mind navigates the intricate path toward transformative breakthroughs, ensuring each discovery is a pivotal step toward the next generation of therapeutics.
Blog
The Inflammation Basis of Metabolic Disease: Understanding the Silent Culprit
Metaflammation fuels the global rise of metabolic diseases, including obesity and type 2 diabetes. Explore the intricate connection between chronic inflammation and these conditions, uncovering potential pharmacological strategies for managing meta-inflammation.
News
First patients dosed in Phase 1a clinical trial of UCL-backed G-Quadruplex (G4) targeting treatment for solid tumors, including pancreatic cancer
A new treatment for G4-targeted solid tumors including pancreatic cancer has been administered…
News
Premiers patients traités dans le cadre de l’essai clinique de phase 1a du traitement ciblé G-Quadruplex (G4) développé par l’UCL contre les tumeurs solides, y compris le cancer du pancréas
Un nouveau traitement ciblant les tumeurs solides G4, dont le cancer du pancréas,…
News
Premiers patients traités dans le cadre de l’essai clinique de phase 1a du traitement ciblé G-Quadruplex (G4) développé par l’UCL contre les tumeurs solides, y compris le cancer du pancréas
Un nouveau traitement ciblant les tumeurs solides G4, dont le cancer du pancréas,…
Blog
Navigating the Future of Protein Glycosylation Analysis: The Rise of Capillary Electrophoresis
Improving the way in which we assess protein expression Capillary electrophoresis is a next generation…
Blog
Pushing drug discovery forward with data-driven purification
Discover how Sygnature Discovery integrates machine learning into HPLC purification, transforming a data-heavy process into a streamlined, automated workflow. This innovation achieves 95% method selection accuracy, saving time and ensuring high-quality compounds for clients.
Blog
It’s All Patently Scientific
Medicinal chemists' inventions go beyond creating molecules; they impact patients. Wide collaboration in design teams enhances patent quality. Routine patent reviews keep us competitive.
Blog
Exploring mechanisms and treatments for Inflammatory bowel disease (IBD): using the DSS mouse model.
Inflammatory bowel disease (IBD) describes multiple inflammatory conditions affecting the gastrointestinal tract, with ulcerative colitis…
Journal Papers
Discovery of Five SOS2 Fragment Hits with Binding Modes Determined by SOS2 X-Ray Cocrystallography
Christopher R. Smith, Dan Chen,James G. Christensen, René Coulombe, James Féthière, Robin J. Gunn, Johan…
Blog
Can iPSC-Derived Microglia Hold the Key to Unlocking Neurodegenerative Mysteries?
Insights into Their Intriguing Behavior and Potential in Neurodegenerative Research
Load More

Support

Can't find what you're looking for?

Can't find what you're looking for? Our team can help — whether you need assistance locating a resource, have a research enquiry, or want media information, get in touch and we'll point you in the right direction.

Get in touch